Don Hayden

Chairman & CEO at WindMIL Therapeutics

Don Hayden brings broad pharmaceutical and biotech experience and insight to his roles at WindMIL. Mr. Hayden had a highly successful 25-year career with the Bristol-Myers Squibb Company and, more recently, at a number of entrepreneurial pharmaceutical and biotech companies. At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group and president of Oncology and Immunology. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of REGENXBIO, Insmed, Vitae Pharmaceuticals, and Gloucester Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals.

Timeline

  • Chairman & CEO

    Current role

View in org chart